8-K: Cue Biopharma Appoints Pasha Sarraf to Board of Directors

Cue Biopharma announces the appointment of Pasha Sarraf to its board of directors, effective March 10, 2025.

Summary

• Cue Biopharma has appointed Pasha Sarraf to its board of directors, effective March 10, 2025.
• The appointment follows the recommendation of the Corporate Governance and Nominating Committee.
• Mr. Sarraf will receive compensation as per the company's Director Compensation Policy.
• Upon appointment, Mr. Sarraf was granted an option to purchase 48,800 shares of the company's common stock, vesting over three years.
• Mr. Sarraf has entered into the company's standard indemnification agreement.

Sentiment

Score: 6

Explanation: The announcement is neutral, detailing a routine board appointment. The sentiment is slightly positive due to the potential benefits of a new board member.

Positives

• The appointment of Pasha Sarraf to the board of directors could bring valuable expertise and insights to Cue Biopharma.

Future Outlook

The company will file a copy of the indemnification agreement with the SEC as an exhibit to its Annual Report on Form 10-K for the year ended December 31, 2024.

Industry Context

Board appointments are a routine part of corporate governance, ensuring companies have experienced leadership and oversight.

Management Changes

Stakeholder Impact

• Shareholders may benefit from the expertise and oversight provided by the new board member.

Next Steps

• The company will file the indemnification agreement with the SEC as an exhibit to its Annual Report on Form 10-K for the year ended December 31, 2024.

Key Dates